Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright

Longeveron (NASDAQ:LGVN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 440.54% from the company’s previous close.

LGVN has been the topic of a number of other reports. Roth Capital raised shares of Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm began coverage on shares of Longeveron in a report on Friday, December 6th. They set a “buy” rating and a $10.00 price target on the stock.

Longeveron Trading Up 5.1 %

Shares of NASDAQ LGVN opened at $1.85 on Friday. The firm has a market capitalization of $27.62 million, a PE ratio of -0.29 and a beta of 0.37. Longeveron has a one year low of $0.77 and a one year high of $6.40. The business has a 50-day moving average price of $1.60 and a two-hundred day moving average price of $1.84.

Institutional Investors Weigh In On Longeveron

Several large investors have recently made changes to their positions in LGVN. State Street Corp bought a new stake in shares of Longeveron in the 3rd quarter valued at approximately $29,000. Northern Trust Corp bought a new stake in shares of Longeveron in the 4th quarter valued at approximately $31,000. Jane Street Group LLC bought a new stake in shares of Longeveron in the 4th quarter valued at approximately $35,000. Virtu Financial LLC bought a new stake in shares of Longeveron in the 4th quarter valued at approximately $53,000. Finally, Geode Capital Management LLC grew its stake in shares of Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares in the last quarter. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.